We are live on ! Find out more
BBP icon

Virtus Biotech ETF
BBP

14 hedge funds and large institutions have $5.22M invested in Virtus Biotech ETF in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more capital inflows, than outflows

Capital inflows: $2.38M | Capital outflows: $1.56M

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

16.78% more ownership

Funds ownership: 0% → 16.78% (+17%)

8% more funds holding

Funds holding: 13 → 14 (+1)

Holders
14
Holders Change
+1
Holders Change %
+7.69%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.58M
2
LPL Financial
LPL Financial
California
+$165K
3
UBS Group
UBS Group
Switzerland
+$127K
4
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$100K
5
Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services
Florida
+$71K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$950K
2
Stifel Financial
Stifel Financial
Missouri
-$611K
3
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$2K

BBP Hedge Fund Activity: Q4 2016 in Review

14 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q4 2016, worth a combined $5.22M — up 17% from $4.45M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BBP positions and 3 closed out — a net gain of 1 holder — while 6 added to existing stakes and 0 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $1.58M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $950K sold.

  • 14 institutional investors held Virtus Biotech ETF (BBP) as of Q4 2016, up from 13 in Q3 2016.
  • Funds reported $5.22M of Virtus Biotech ETF stock for Q4 2016, up 17% quarter-over-quarter.
  • 4 funds opened new Virtus Biotech ETF positions in Q4 2016 and 3 closed out, a net change of +1 holder.
  • The largest Virtus Biotech ETF buyer in Q4 2016 was Royal Bank of Canada, an estimated $1.58M added.
  • The largest Virtus Biotech ETF seller in Q4 2016 was Susquehanna International Group, an estimated $950K sold.

Based on aggregated 13F filings for Q4 2016.